A change in thinking by the US FDA on the similarity requirement in clinical efficacy studies for biosimilars of Genentech Inc.'s Avastin (bevacizumab) may have forced delays, or at least recalculations, for several potential candidates.
During the Oncologic Drugs Advisory Committee review of Amgen Inc. and Allergan PLC's ABP215 on July 13, FDA...






